By integrating gene profiling and immunohistochemical data with functional experiments in cell lines in this study we show for the first time that doublecortin (DCX) domain containing 2 (DCDC2), a protein belonging to the DCX family and involved in neuronal cell migration, is aberrantly expressed in prostate tumors whereas absent in normal prostate. Furthermore, in patients treated with radical prostatectomy, high levels of DCDC2 RNA were significantly associated with increased biochemical relapse (LogRank Mantel-Cox ¼ 0.012). Mechanistically, we found that the ETS transcription factor ESE3/EHF, which is expressed in normal prostate and frequently lost in prostate tumors, maintained DCDC2 repressed by binding to a novel identified ETS binding site in the gene promoter. Consistently, in prostate tumors and in cellular models of gain and loss of ESE3/EHF, the expression of DCDC2 and ESE3/ EHF were inversely correlated. In prostate cancer cells, DCDC2 colocalized with microtubules and promoted cell migration and resistance to the microtubule-targeting drug taxol. Collectively, this study establishes DCDC2 as a novel ESE3/EHF oncogenic target in prostate cancer. These findings may be relevant for the clinical management of prostate cancer as DCDC2 may signal tumors more prone to relapse and resistant to taxol treatment.
INTRODUCTION
Prostate cancer is the most common cancer and a leading cause of cancer death in western countries. 1 Mortality is mostly due to metastatic disease and development of castration-resistant prostate cancer. Improving the management of prostate cancer will require early diagnosis and appropriate therapeutic decisions based on a better understanding of the underlying molecular events affecting the progression of the disease. The androgen receptor has an important role in prostate cancer initiation and progression to castration resistance. 1 In addition to androgen receptor, transcription factors of the ETS gene family have emerged as important elements in the pathogenesis of prostate cancer. [2] [3] [4] Chromosomal translocations and gene rearrangements leading to ectopic expression of ETS genes occur in about 50% of primary tumors. [2] [3] [4] Translocated ETS factors have oncogenic activity promoting cell transformation, proliferation and survival. [5] [6] [7] [8] [9] We reported recently that the epithelial-specific ETS factor EHF/ESE3, which is expressed in normal prostate epithelial cells, has tumor-suppressor function and is frequently downregulated in prostate tumors due at least in part to epigenetic events. 10 In this study, we identified for the first time that the gene encoding the neuronal-specific doublecortin (DCX) domain containing 2 (DCDC2) protein as an ETS target gene that is upregulated as consequence of ESE3/EHF loss in prostate tumors. DCDC2 belongs to the DCX family of proteins characterized by the presence of DCX domains. 11, 12 The DCX repeat gene family is composed of eleven prologs in humans and in mice. DCX proteins are involved in the neuronal migratory activity during cortex development. [13] [14] [15] Mutations in the human DCX gene, the first characterized gene of the family, result in abnormal neuronal migration, epilepsy, mental retardation and cause double cortex syndrome and lissencephaly in humans. 11 Downregulation of DCX by RNA interference in animal models leads to neuronal migration disorders similar to those seen in the brains of dyslexic individuals. 13, 16 DCDC2 is a brain-specific protein interacting with microtubules and involved in neuronal migratory activity 13, [15] [16] [17] [18] Mutations in the DCDC2 gene have been associated with dyslectic reading disabilities due to abnormal neuronal migration. 13 Our finding of high expression of DCDC2 in prostate tumors was intriguing because the level of DCDC2 is negligible in many normal tissues including prostate. The restricted pattern of expression of DCDC2 and its specialized function in neuronal brain migration suggested that DCDC2, when ectopically expressed in prostate epithelial cells, could confer abnormal properties contributing to cell transformation and tumorigenesis. Consistent with this hypothesis, we found that high expression of DCDC2 was associated with increased biochemical relapse in patients after radical prostatectomy. Mechanistically, DCDC2 expression was negatively regulated by ESE3/EHF and reactivated upon loss of ESE3/EHF in prostate cancer cells. Functionally, ectopic expression of DCDC2 affected migration and resistance to taxol in prostate cancer cells. Collectively, this study identifies a novel oncogenic target regulated by the ETS factor ESE3/EHF in prostate tumors with potential relevance as diagnostic, prognostic and predictive biomarker.
RESULTS

DCDC2 is aberrantly expressed in prostate cancers
To identify genes that mark the molecular transition from benign prostate to invasive carcinoma, we performed differential gene expression profile analysis on a previously published gene expression profiling data set of normal prostate and primary prostate cancers. 19 We focused particularly on ectopically expressed genes, that is, genes that are not expressed in adult normal prostatic tissue and whose expression would indicate the activation of an abnormal differentiation program in tumor cells. In addition to their biological relevance in the process of malignant transformation, such genes could be relevant as potential diagnostic and prognostic biomarkers and targets for therapeutic intervention. Among the significantly differentially expressed genes, we found DCDC2 (FDR ¼ 0.002), a gene encoding a neuronal-specific protein involved in neuronal migration and brain development and not expressed in most adult tissues.
17 DCDC2 was significantly increased in prostate tumors compared with normal prostate samples ( Figure 1a , left panel). In the microarray data set about half (55%) of tumors had a X2 increase of DCDC2 mRNA compared with normal prostate and 17% of tumors had an increase of X3 fold (Figure1a, right panel). To confirm this finding, we measured DCDC2 mRNA by quantitative real-time-PCR (qRT-PCR) in an independent set of formalin-fixed paraffin embedded (FFPE) primary prostate cancer samples. DCDC2 was expressed in about 60% of the tumors, although it was undetectable by qRT-PCR in the remaining cases (Figure 1b) , consistent with the percentage of DCDC2 positive tumors in the microarray data set.
To assess the clinical relevance of this finding, we determined whether expression of DCDC2 was associated with clinical outcome in prostate cancer patients treated with radical prostatectomy. Clinical follow-up data were available for patients in the two cohorts for which we had DCDC2 mRNA level determined by microarray and qRT-PCR, respectively. In both cohorts we divided patients based on the DCDC2 mRNA level in three groups: low (L) intermediate (I) and high (H) DCDC2 expressing tumors. Interestingly, Kaplan-Meier analysis using DCDC2 expression level from array data, indicated that the probability of biochemical recurrence-free survival in patients with high level of DCDC2 was significantly higher than in patients with low and intermediate level of DCDC2 mRNA (Log-rank Mantel-Cox test ¼ 0.012) (Figure 1c ). The association between increased level of DCDC2 and biochemical relapse was also observed in the cohort of FFPE prostate patients analyzed by qRT-PCR (Figure 1d ), although the difference was not statistically significant (Log-rank Mantel-Cox test ¼ 0.09). Collectively, these data show for the first time the aberrant expression of DCDC2 in prostate tumors and its association with increased biochemical relapse and more aggressive disease behavior.
Expression of the neuronal-specific gene DCDC2 in prostate tumors might be part of an altered differentiation program whose various elements would contribute to tumorigenesis. To understand whether DCDC2 expression was associated with altered expression of other tumor promoting factors we performed a correlation analysis using the available prostate cancer microarray dataset. We find 589 genes positively correlated (Pearson score 40 and P value o0.05) and 669 genes negatively correlated to DCDC2 (Pearson score o0 and P value o0.05) (Supplementary Table S1 ). Functional annotation analysis revealed that the genes positively correlated with DCDC2 were functionally related to cell pathways linked to cell transformation and tumor progression such as angiogenesis, signal transduction, cell migration and inflammation (Figure 1e ). The list of positively correlated genes included known oncogenic targets with tumor promoting functions such as MMP19, IL1B and chemokine receptor CXCR4 among others. Intriguingly, the genes negatively correlated to DCDC2 were associated prevalently to chromatin and nucleosome assembly. Although this might suggest an association with altered epigenetic control mechanisms, understanding the significance of this finding would require further studies.
Expression of DCDC2 is negatively regulated by ESE3/EHF To validate the finding of aberrant expression of DCDC2 in prostate tumors at the protein level, we performed immunohistochemical staining with an anti-DCDC2 antibody on tissue microarrays containing specimens of normal prostate (n ¼ 47) and matching organ-confined prostate tumors (n ¼ 50). DCDC2 immunostaining was negative in 90% of the cases and weakly present only in 10% of normal prostate samples, confirming that the protein is generally not expressed in normal adult tissues (Figures 2a,b) . About 30% of prostate tumors were negative, while 28 and 42% of the cases were, respectively, weakly and strongly positive for DCDC2 (Figures 2a,b) . DCDC2 immunostaining was prevalently cytoplasmic and more abundant in the perinuclear region both in normal and tumor samples (Figure 2b ). Thus, immunohistochemical assessment of DCDC2 level reinforced the RNA data confirming that DCDC2 is absent in normal prostate and is expressed in a high percentage of prostate tumors.
The absence of DCDC2 in normal prostate and its frequent reexpression in prostate tumors suggested that the event could be linked to malignant transformation and be part of the dedifferentiation program induced by oncogenic events in prostate epithelial cells. Therefore, we were interested in understanding the mechanisms controlling DCDC2 expression in these cells. Interestingly, correlation analysis in normal and prostate cancer microarray data revealed that the ETS transcription factor ESE3/ EHF was inversely correlated to DCDC2 (P ¼ 0.01)(Supplementary Table S1 ). When we confronted the data on immunohistochemical staining for DCDC2 and ESE3/EHF in tissue microarray we found a similar inverse association between the two proteins. Interestingly, 54% of prostate tumors with reduced ESE3/EHF expression (ESE3-Low) were positive for DCDC2. In contrast, 86% of ESE3 positive (ESE3-Pos) tumors were DCDC2 negative. These data suggested that expression of DCDC2 could be at least in part controlled by ESE3/EHF in prostate tumors. ESE3/EHF is an ETS transcription factor with tumor-suppressor function and frequently lost in prostate tumors. 12 Thus, we hypothesized that transcription of DCDC2 was negatively controlled by ESE3/EHF in normal prostate epithelial cells and reactivated as a consequence of ESE3/EHF downregulation in cancer cells.
To further define the link between ESE3/EHF and DCDC2, we determined whether there was a relationship between ESE3/EHF and DCDC2 expression in prostate cancer cell lines. As shown in Figure 3a , DCDC2 was absent in ESE3/EHF positive LNCaP cells although it was highly expressed in ESE3/EHF negative DU145 cells. To functionally link DCDC2 expression with ESE3/EHF loss in prostate cancer cells, we evaluated the expression of DCDC2 in LNCaP cells with stable knockdown of ESE3/EHF (ESE3-KD). 19 In multiple ESE3-KD LNCaP clones, we observed a consistent increase of DCDC2 mRNA and protein ( Figure 3b ). Conversely, stable reexpression of ESE3/EHF in DU145 cells, reduced significantly the level of DCDC2 mRNA and protein compared with control cells (Figure 3c ).
Thus, our data indicated that the expression of ESE3/EHF and DCDC2 was inversely correlated in human tumor samples and cell lines, and suggested that ESE3/EHF could maintain the gene in a repressive state. We showed previously that ESE3/EHF could act as a transcriptional repressor in addition to possessing transcriptional-activating functions depending on the promoter context. The DCX domain binds tubulin and enhances microtubule polymerization. 15, 18 We analyzed the subcellular localization of DCDC2 in prostate cancer cells by immunofluorescence microscopy. We were interested in determining DCDC2 localization and eventual association with microtubules when it is ectopically expressed in prostate cancer cells. In DU145 cells, DCDC2 was present predominantly in the cytoplasm with a ring-like distribution surrounding the nucleus (Figure 4 , left panels), which is reminiscent of the pattern observed for DCX in primary cortical neuron. 17 Staining with an a-tubulin antibody showed a large overlap between DCDC2 and microtubules. The DCDC2 appearance was punctuated than the a-tubulin immunostaining. However, the merge revealed significant areas of colocalization of the two proteins. The regions of overlap between DCDC2 and a-tubulin immunoreactivity were mostly surrounding the nucleus. This pattern of colocalization was consistent with that observed with DCX and other microtubules-associated protein (MAP) like tau. [20] [21] [22] Consistent with the ESE3/EHF repressive effect on DCDC2 expression, there was very little staining for DCDC2 in DU145 cells stably expressing ESE3/EHF (Figure 4a ). Interestingly, a-tubulin immunostaining was similar in DCDC2 positive and negative DU145 cells, suggesting that DCDC2 expression did not affect a-tubulin expression and distribution. A similar pattern of intracellular distribution and colocalization with microtubules was seen in ESE3-KD LNCaP cells in which DCDC2 was reexpressed ( Figure 4a , right panels). Instead, as in parental LNCaP cells, DCDC2 was undetectable in control (small hairpin RNA) shRNA transfected LNCaP cells. Colocalization of DCDC2 and a-tubulin in DU145 cells was confirmed by confocal microscopy (Figure 4b ). To further understand whether DCDC2 and a-tubulin directly interacted we performed coimmunoprecipitation using DCDC2 and a-tubulin antibodies. We observed that DCDC2 coimmunoprecipitated with a-tubulin (Figure 4c) . Collectively, these data show for the first time the DCDC2 intracellular localization in prostate cancer cells and indicate a direct interaction of the protein with microtubules also in the prostate-cell context.
Interaction between the DCX domain and microtubules has been associated to the migratory activity in brain neurons. Consistently, it has been reported that local loss of function of DCDC2 induced by RNA interference result in the interruption of normal neuronal migration. 13 Thus, we hypothesize that reexpression of DCDC2 in prostate cells could alter the cell migratory capability. To test this, we used RNAi to knockdown DCDC2 in DU145 and ESE3-KD LNCaP cells. Successful DCDC2 knockdown was documented at the RNA level (Figure 5a ). Figure 2A) and resulted in a significantly reduced cell migration as assessed by wound healing (Figure 5c and Supplementary Figure 2B ) and Boyden chamber assay in DU145 (Figure 5d ). In contrast, knockdown of DCDC2 did not affect cell proliferation (Supplementary Figure 2C) . Collectively, these results indicate that DCDC2 has a direct role in cell migration and that reexpression of the gene following ESE3/EHF loss is associated with the acquisition of a migratory phenotype in prostate epithelial cells.
DCDC2 is involved in taxol resistance DCX proteins are MAPs and data showed above indicate that DCDC2 colocalizes with microtubules in prostate cancer cells.
Microtubules are essential components of the cytoskeleton and have a critical role in many cellular process including cell motility and shape maintenance. 23, 24 Their dynamic properties are crucial for the assembly of the mitotic spindle and attachment of chromosomes along the spindle. Microtubule-targeting drugs, such as taxol, bind to tubulin and enhance microtubule polymerization. 23, 24 MAP, by binding to tubulin, can alter microtubule dynamics and thus the sensitivity of cells to microtubule-targeting drugs. 23, 24 Indeed, expression of various MAPs has been linked to the level of sensitivity of cancer cells to microtubule-targeting drugs. 22, 25, 26 High levels of tau, a MAP protein related with DCDC2, have been associated with resistance DCDC2 is overexpressed in prostate cancer N Longoni et al to taxol in breast cancers 22 and loss of tau expression sensitized breast cancer cells to taxol, consistent with its function in microtubule stabilization. 22 Therefore, we hypothesized that DCDC2 could alter the response of prostate cancer cells to taxol by virtue of its ability to interact with microtubules. In keeping with this hypothesis, we observed that the apoptotic response to taxol, measured by PARP cleavage, was active in LNCaP cells expressing ESE3/EHF, although it was greatly attenuated in ESE3-KD LNCaP cells (Figure 6a) . Furthermore, cytotoxicity assays showed that ESE3-KD LNCaP cells were more resistant than parental LNCaP cells to taxol-induced cell death (Figure 6b ). This effect was clearly linked to ESE3/EHF expression level with loss of ESE3, resulting in increased resistance to taxol. Therefore, we wondered whether reexpression of DCDC2 in ESE3-KD cells could contribute to the induction of taxol resistance.
To determine the role of DCDC2, we knocked down DCDC2 in ESE3-KD LNCaP cells and evaluated the effects of taxol in cytotoxicity assays. Parental LNCaP cells were highly sensitive to taxol and transfection with a siRNA specific for DCDC2 did not affect their response to the treatment (Figure 6c ). In contrast, we observed a significant decrease in the percentage of viable cells upon knockdown of DCDC2 in ESE3-KD LNCaP cells, which overexpress DCDC2. Consistently, reexpression of DCDC2 by transfection of an expression vector in LNCaP cells resulted in increased resistance to taxol (Figure 6d) . Furthermore, knockdown of DCDC2 in DU145 cells resulted in a significant increased Figure 3) . Collectively, these studies identify a novel mechanism of taxol resistance in prostate tumors mediated by the aberrant expression of DCDC2.
DISCUSSION
In this study, we show that the gene encoding DCDC2 is a novel oncogenic target activated in prostate tumors. DCDC2 is a member of the DCX protein family, which is characterized by the presence of DCX peptide domains. 17 The DCX gene, located on the X chromosome and the first characterized gene of the family, encodes a cytoplasmic protein that directs neuronal migration by regulating the organization and stability of microtubules. Mutations in the human DCX gene causes double cortex syndrome and lissencephaly in humans. 27 In both diseases the point mutations cluster within the conserved DCX peptide motifs of DCX that serve as protein-interaction platforms and interaction with microtubules.
Here we report that DCDC2 is ectopically expressed in about 50% of prostate tumors, whereas it is absent in normal prostate. By integrating gene expression profile and tissue microarray data in human tumors with experiments in human cancer cell lines, we show that ectopic expression of this neuronal protein in prostate tumors is associated with oncogenic transformation and tumor progression. Our data indicate that in prostate tumors high expression of DCDC2 is associated with worse prognosis and significantly shorter relapse-free survival. Interestingly, DCX has DCDC2 is overexpressed in prostate cancer N Longoni et al been proposed as a molecular marker to detect minimal residual disease in neuroblastoma. 28, 29 Moreover, DCX was reported to be preferentially expressed in invasive human brain tumors. 30 Thus, our results are consistent with the notion that aberrant expression of DCX family proteins in human tumors may have clinical relevance and suggest that a member of this family, DCDC2, may be particularly relevant in the context of prostate tumors. This finding deserves further investigation as expression of DCDC2 may mark tumors with a higher degree of dedifferentiation and particularly aggressive features.
The restricted pattern of expression of DCDC2 in prostate tumors and its almost complete absence in normal tissue suggested a close link to oncogenic transformation. We investigated the mechanism leading to DCDC2 activation in prostate cancer. We showed previously that the ETS transcription factor ESE3/EHF is present in normal prostate and downregulated in prostate tumors. 10 Through analysis of microarray and immunohistochemical data, we found that the DCDC2 expression was inversely correlated with ESE3/EHF. A similar inverse correlation was found in prostate cancer cell lines supporting a link between reduced expression of ESE3/EHF and activation of DCDC2 transcription. Furthermore, knockdown of ESE3/EHF led to expression of DCDC2, although re-expression of ESE3/EHF in cancer cells reduced the level of DCDC2. Consistently, we identified an ETS binding site in the DCDC2 promoter and confirmed by chromatin immunoprecipitation the binding of ESE3/EHF to the DCDC2 promoter in cells that do not express DCDC2. Thus, the epithelial-specific ETS factor ESE3/EHF maintains the DCDC2 gene repressed, preventing its aberrant expression in prostate epithelial cells.
These results uncover also an important mechanism by which ESE3/EHF could exert its tumor-suppressor function, that is, by preventing the expression of proteins contributing to the acquisition of migratory capability and metastatic phenotype. Indeed, functional experiments showed that DCDC2 expression increased in vitro cell migration. Intriguingly, although the effect on cell migration was consistent with the role of DCDC2 in neuronal cells, this work identifies an additional and potentially clinically relevant consequence of aberrant expression of DCDC2 in prostate tumors. We found that DCDC2 expression was associated with increased resistance to taxol in prostate cancer cells. This effect is likely linked to the ability of the DCDC2 to interact with microtubules and interfere with taxol-induced disruption of microtubule function and the consequent activation of the apoptotic cascade. Members of the DCX protein family bind to microtubules through their conserved DCX motifs, promoting microtubule assembly and stabilization. 15, 17, 18, 31 We observed colocalization of DCDC2 with microtubules in prostate cancer cells, and direct interaction of DCDC2 with a-tubulin, suggesting that DCDC2 could act through a similar mechanism of microtubule stabilization to alter the sensitivity of prostate cancer cells to taxol. Altered expression of other MAPs, like tau, has been shown to be associated with taxol resistance in breast cancer.
22 DCDC2 could have a similar effect when overexpressed in prostate tumors and mark tumors potentially less responsive to taxol treatment.
Overall, the present data highlight a novel ETS-related oncogenic target in prostate cancer. We found that DCDC2 is involved in cell migration and taxol resistance in prostate cancer cells and is negatively associated with disease recurrence. Future studies are warranted to explore the clinical relevance of DCDC2 
MATERIALS AND METHODS
Microarray data analysis
Gene expression profiling of normal prostate and tumor samples has been previously described and patient characteristics reported. 10 Gene expression analysis was performed on Agilent Human 1A glass arrays using a dye-swap replication scheme. Data are MIAME compliant and have been deposited in the Gene Expression Omnibus (GEO accession number. GSE14206). A commercial pool of RNA from organ donor healthy prostates (Becton Dickinson, Buccinasco, Milano, Italy) was used as common reference. To identify differentially expressed genes between normal and tumor samples a log2 gene expression matrix was created after combining dye-swap replicates. Expression data were then filtered for s.d.40.5 across the samples, giving a matrix containing 5142 probes. Differential gene expression analysis between sample classes was performed on the 5142-gene matrix using Gene Expression Profile Analysis Suite. Differentially expressed genes were obtained after filtering for q-value (Qp0.1). To identify genes correlated and anticorrelated with DCDC2, we used the R function correlation test (), which provides Pearson's correlation coefficient.
Patient samples
Tissue samples from the FFPE tissue cohort used for qRT-PCR validation of DCDC2 were obtained from patients with organ-confined prostate cancer treated with radical prostatectomy at Hospital of Biella (Italy), between 1993 and 1998, and collected with the approval of the Ethical Committee of the Piedmont Region and patient's written informed consent.
Samples for immunohistochemical studies were obtained from surgically treated patients with organ-confined prostate cancer at the IRCCS (Italian Research Hospital) Multimedica, Italy, with the approval of the Regione Lombardia Ethical Committee and patient's written informed consent.
RNA extraction from tumor samples and qRT-PCR RNA was extracted from tissue sections from archival FFPE samples. Two expert pathologists (FS and GD) selected the area to be processed. Briefly, for every tissue-block a slice was stained with H&E and evaluated to identify areas enriched of tumoral lesions (at least 75% of tumor cells). Subsequent slices were used to isolate RNA from macrodissected areas based on the H&E staining. Tissue were deparaffinized with ethanol and RNA was extracted using RNeasy Mini Kit (Qiagen, Hombrechtikon, Switzerland) and then treated with DNase. QRT-PCR was performed using SYBR Green qPCR. Primer sequences are shown in supplementary Table S2 .
Survival analysis
Kaplan-Meier survival curves were created using SPSS software version 17.0 (IBM SPSS, Chicago, IL, USA). The log rank test was applied to examine the relationship between DCDC2 expression and biochemical progressionfree survival. The level of DCDC2 in the microarray data set was defined as low (L), Intermediate (I) and High (H), whether it was, respectively, o2, X2 and 4threefold different from the value in normal prostate samples. Biochemical recurrence was defined as a 0.2 ng/ml increase in prostate specific antigen with a second confirmatory prostate specific antigen measurement 40.2 ng/ml. Patients were censored at the time of the last clinical follow-up. For the microarray data set, 19 patients included in the analysis (n ¼ 28) had completed eight years of follow-up, had been treated with radical prostatectomy and had not received any treatment before and following surgery until the time of relapse. For the archival patients FFPE data set, the same criteria were applied and patients included in the analysis (n ¼ 27) had completed 13 years of follow-up. Patient's analysis is summarized in Supplementary Figure 4 .
Immunohistochemistry
Tissue microarrays containing samples from normal and adenocarcinoma tissues were prepared from FFPE tissues as previously described. 32 Sections were dewaxed in xylol, rehydrated in ethanol and treated with antigen retrieval solution (DAKO, Glostrup, Denmark) as recommended by the manufacturer. Immunohistochemistry was carried out using anti-DCDC2 rabbit polyclonal antibody (1:200 dilution, Sigma, Buchs, Switzerland) and anti-ESE-3 (Clone 5A5.5) rat monoclonal antibody (1:75 dilution, LabVision Corporation, Fremont, CA, USA) followed by incubation with a secondary mouse anti-rat antibody (DAKO). Samples, in which the primary antibody was omitted, were included as negative controls. Staining was independently scored by three expert pathologists.
Cell culture, transfection and drug treatment LNCaP and DU145 were obtained from American Type Culture Collection and maintained in RPMI-1640 supplemented with 10% fetal bovine serum as previously described.
19 ESE3/EHF expressing DU145 cells were generated after transfection with ESE3/EHF expression vector and selected with G418. 10 Negative control cells were obtained by transfection with pcDNA3.1 (Invitrogen, Zug, Switzerland) and selection in G418. LNCaP stably expressing ESE3 targeting shRNAs were established as previously described. 19 For transient gene knockdown, cells were transfected with siRNAs targeting DCDC2 or control siRNA using Interferin. 10 Alternatively, sh plasmid containing siRNA against DCDC2 or control sh (SABiosciences, QIAGEN AG, Hombrechtikon, Switzerland) were transfected in DU145 cells with JetPrime reagent (Polyplus-transfection SA, Illkirch, France), according to manufacturers protocol. For DCDC2 overexpression DCDC2-V5 plasmid containing full length DCDC2-GFP tagged (kindly provided by Dr Satu Massinen 33 ) and pcDNA were transfected using JetPrime (PolyplusTransfection SA, Illkirch, France). Transfection efficiency was assessed evaluating GFP positive cells by microscopy and Western-blot (data not shown). Cell proliferation was assessed 48 and 72 h after transfection using a colorimetric assay (MTT, Sigma) and reading absorbance at 540 nM in a microplate reader. 34 Taxol treatment was performed in 96-well plates and cell viability measured with MTT as described above. All assays were done in triplicate and repeated in three independent experiments.
Luciferase promoter assay
Luciferase assays were carried out as previously described 19 using a luciferase promoter reporter containing 600 base pairs of the DCDC2 promoter region (kindly provided by Dr Jeffrey Gruen). 35 
Cell migration
To assess cell migration in wound healing/scratch assays cells were grown to confluence in six-well plates and then overnight in serum-free medium. Then, scratches were performed on the cell monolayer, complete medium was added and cells monitored for 24-48 h using a Zeiss Axiovert microscope equipped with Axiocam Mrc3 (Carl Zeiss AG, Feldbach, Switzerland). For quantitative analysis wound size was measured at each time point in triplicate wells and data represent the average of multiple experiments. For the Boyden chamber assay, 24-well Insert System with an 8 mM PET membrane (BD Bioscience, Allschwil, Switzerland) was coated with Collagen type IV (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland). Cells were added to the top of chamber in RPMI with 0.1% BSA. Using DU145 conditioned media as chemoattractant, cells were incubated at 37 1C for 24 h. After incubation, nonmigrating cells were carefully removed from the top of each insert with a cotton swab. Migrating cells were fixed, stained and counted microsopically using Zeiss Axiovert (X100 objective) to determine the extent of cell migration. The assays were done in triplicate and repeated in three independent experiments.
RT-PCR and immunoblotting
RNA was extracted from cell lines using Trizol (Invitrogen) and treated with DNase I to remove any contaminant genomic DNA. Conventional real-time PCR (RT-PCR) was performed as described previously 10 using SuperScript One-step RT-PCR System (Invitrogen). PCR products were analyzed by gel electrophoresis and visualized using the AlphaImager 3400 (Proteinsimple, Santa Clara, CA, USA). Cell lysate preparation, gel electrophoresis and immunoblotting were performed as described previously 10 using antibodies against DCDC2 (Santa Cruz Biotechnology Inc., Heidelberg, Germany), ESE3/EHF (Clone 5A5.5, Lab Vision, Fremont CA, USA), cleaved PARP (BD Pharmingen, Switzerland), and a-tubulin (Santa Cruz Biotechnology Inc). For immunoprecipitation, DU145 and LNCaP cells were lysed in RIPA Buffer (50 mM Tris-HCl ph 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP40, 0.25% Na-deocycholate, 1 mM PMSF, 1 mM NaF, 1X (Roche, Basel, Switzerland) complete mini protease inhibitor cocktail). Protein extracts (200 mg) were incubated with anti-DCDC2 and anti-a-tubulin antibodies overnight at 4 1C and then incubated with protein G agarose beads for 4 h. The beads were washed with RIPA buffer four times and then eluted DCDC2 is overexpressed in prostate cancer N Longoni et al
